Multiple Myeloma Coverage From Every Angle
Advertisement
Advertisement

Recent News

Multiple Myeloma Precursor Disease in World Trade Center Firefighters
FDA Approves Daratumumab in Combination With VMP for Newly Diagnosed Multiple Myeloma
Multiple Myeloma Research Foundation Awards $7M to Advance Immunotherapy Research
Comparing Donor Lymphocyte Infusions for Myeloid Malignancies
Melphalan Conditioning Regimens Compared in Patients With Multiple Myeloma
FDA Lifts Clinical Hold on Studies of BPX-501
FDA Grants Fast Track Designation to Selinexor for Refractory Multiple Myeloma
EBMT 2018: Induction Therapy Prior to Surgery in Patients With Multiple Myeloma
How Common Is Cognitive Impairment Among Older Patients With Blood Cancers?
Private Foundation Funds Translational Research in Multiple Myeloma
Drug Combination Tested in Those With Resistant Myeloma and Renal Impairment
CAR T-Cell Therapy Clinical Trial Enrolling Patients With Myeloma
Amifostine in Reducing GI Toxicity in Myeloma Patients After Marrow Transplant
FDA Grants Orphan Drug Status to Novel Chemotherapy Agent for Multiple Myeloma
First-in-Class Treatment Option for Resistant Myeloma
Racial Disparities in Use of Multiple Myeloma Therapies
Newly Uncovered Role for Protein in Multiple Myeloma
FIRST Trial: Survival Outcomes in Transplant-Ineligible Multiple Myeloma
Double Versus Single Autologous Stem Cell Transplantation in Multiple Myeloma
FDA Grants Priority Review to Front-Line Combination Therapy for Multiple Myeloma
Predicting Outcomes in Newly Diagnosed Myeloma After Initial Relapse
Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma
Investigational CAR T-Cell Therapy in Relapsed Multiple Myeloma
Gene-Expression Profiling in Newly Diagnosed Multiple Myeloma
Minimal Residual Disease in Multiple Myeloma: Surrogate Biomarker for Trial Evaluation?
FDA Grants Approval for Denosumab in the Prevention of Skeletal-Related Events in Patients With Multiple Myeloma
NCI-Designated Cancer Care Versus Community Cancer Care for Multiple Myeloma
Curative Strategy for High-Risk Smoldering Myeloma
ASH 2017: Adding Carfilzomib to Lenalidomide and Dexamethasone in Relapsed or Refractory Myeloma
ASH 2017: Busulfan Plus Melphalan Versus Melphalan Alone in Multiple Myeloma
ASH 2017: Antibiotics to Counteract Infections in Newly Diagnosed Patients With Myeloma
ASH 2017: ASCT Versus Three-Drug Combination in Newly Diagnosed Multiple Myeloma
ASH 2017: Adding Daratumumab to VMP in Newly Diagnosed Multiple Myeloma
ASH 2017: Subcutaneous Delivery of Daratumumab in Relapsed or Refractory Myeloma
ASH 2017: BCMA-Targeted Therapy in Relapsed or Refractory Multiple Myeloma
ASH 2017: Daratumumab in Intermediate- or High-Risk Smoldering Multiple Myeloma
ASH 2017: CAR T-Cell Therapy in Heavily Pretreated Patients With Myeloma
MCRI Provides Funding for Novel Multiple Myeloma Research
Limiting Antigen Escape in Patients With Relapsed Multiple Myeloma
Dose-Escalation Study of CLR 131 in Relapsed or Refractory Multiple Myeloma
Potential of Diuretic Amiloride in Multiple Myeloma
Role of NGLY1 in Multiple Myeloma Treatment Resistance
AORTIC 2017: Patient Access to Hematopoietic Stem Cell Transplantation in Sub-Saharan Africa
FDA Approves Letermovir to Prevent Cytomegalovirus Infection in Patients Who Receive HSCT
Effect of UTX Loss in Multiple Myeloma
Once-Weekly vs. Twice-Weekly Carfilzomib in Relapsed or Refractory Myeloma
2017 Palliative Care Symposium: Sexual Dysfunction Intervention for HCT Survivors
Long-Term Impact of ASCT in Patients With Multiple Myeloma
2017 NCCN Hematologic Malignancies Congress: Managing Common Complications of Myeloma and Its Treatment
2017 NCCN Hematologic Malignancies Congress: Managing Newly Diagnosed Transplant-Eligible Myeloma Patients
2017 NCCN Hematologic Malignancies Congress: Treatment Update on Relapsed or Refractory Multiple Myeloma
Bortezomib Plus Hsp90 Inhibitor in Relapsed or Refractory Multiple Myeloma
Comparison of Two Lenalidomide-Based Triplets in Newly Diagnosed Multiple Myeloma
Combination Treatment in Newly Diagnosed Patients With Multiple Myeloma
New Drug Combination in Newly Diagnosed Multiple Myeloma
Ixazomib-Based Triplet Therapy for Newly Diagnosed Multiple Myeloma
Comparison of Two Induction Therapies for Newly Diagnosed Multiple Myeloma
ESMO 2017: Infusion-Related Reactions in Myeloma Patients Treated With Daratumumab
Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma
Elotuzumab Combination Therapy for Relapsed or Refractory Myeloma
Isatuximab Combination Therapy for Relapsed or Refractory Multiple Myeloma
Daratumumab Triplet Approved for Relapsed or Refractory Myeloma
CAR-T Therapy for Refractory or Relapsed Multiple Myeloma
Maintenance Therapy With Ixazomib Without Stem Cell Transplant in Patients With Myeloma
FDA Statement on Safety Concerns Related to Investigational Use of Pembrolizumab in Multiple Myeloma
Denosumab vs. Zoledronic Acid in Myeloma-Related Bone Disease